AKT1 and non-small cell lung carcinoma: Memmott et al. (21) found that lipid-based AKT inhibitors, phosphatidylinositol ether lipid analogs (PIA), activate AMPK independently of LKB1 in LKB1-mutant non-small cell lung cancer (NSCLC) cell lines.